Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

Background: Numerous studies have reported favorable outcomes using drug-coated
balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial …

Background—Randomized controlled trials have reported favorable 1-year outcomes with
drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease …

Background: While randomized trials have demonstrated the superiority of drug-coated
balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in …

Purpose: To assess the safety and effectiveness of the MDT-2113 (IN. PACT Admiral) drug-
coated balloon (DCB) for the treatment of de novo and native artery restenotic lesions in the …

Background: Evidence from large, randomized, controlled peripheral artery disease trials
reporting long-term outcomes using drug-coated balloons (DCBs) is limited. Previously, the …

Objectives: The authors sought to evaluate the performance of the Ranger paclitaxel-coated
balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months …

Objectives: The aim of this study was to appraise 2-year outcomes after percutaneous
transluminal angioplasty of long femoropopliteal artery disease using paclitaxel-coated …

Background The treatment of peripheral artery disease with percutaneous transluminal
angioplasty is limited by the occurrence of vessel recoil and restenosis. Drug-coated …

Background The IN. PACT Global Study was an international prospective single-arm clinical
trial to evaluate the safety and effectiveness of a drug-coated balloon in the treatment of …